Uchaĭkina L V, Vakhliaev V D
Kardiologiia. 1990 Feb;30(2):24-9.
Intravenous finoptin (verapamil), 10 mg, was tested for effects on the coronary venous blood flow by probing the coronary sinus and great vein of the heart and performing atrial pacing in 24 patients with ischemic heart disease and eukinetic central hemodynamics. In persons who had had initial high blood flow in the coronary sinus, the agent was found to induce resting coronary venous blood flow changes which were inadequate for its demand and during cardiac pacing; whereas in patients with mean initial venous blood flow values, finoptin enabled myocardial oxygen consumption to be provided both in the region of non-infarcted myocardium and in the ischemic area.
对24例缺血性心脏病且中心血流动力学正常的患者，通过探测冠状窦和心脏大静脉并进行心房起搏，测试了静脉注射10毫克的异搏定（维拉帕米）对冠状静脉血流的影响。在冠状窦初始血流较高的患者中，发现该药物在静息状态及心脏起搏时诱导的冠状静脉血流变化无法满足需求；而在初始静脉血流均值的患者中，异搏定能够在非梗死心肌区域和缺血区域提供心肌氧消耗。
